Hostname: page-component-7c8c6479df-ph5wq Total loading time: 0 Render date: 2024-03-28T10:00:04.830Z Has data issue: false hasContentIssue false

n-3 Polyunsaturated fatty acids and trans fatty acids in patients with the metabolic syndrome: a case–control study in Korea

Published online by Cambridge University Press:  28 February 2008

Eunjeong Lee
Affiliation:
Department of Food and Nutrition, Hanyang University, Seoul, Korea
Sangyeoup Lee
Affiliation:
Center for Obesity Nutrition and Metabolism, Family Medicine Division, Pusan National University Hospital and Medical Research Institute, Pusan National University, Pusan, Korea
Yongsoon Park*
Affiliation:
Department of Food and Nutrition, Hanyang University, Seoul, Korea
*
*Corresponding author: Professor Yongsoon Park, fax +82 2 2292 1226, email yongsoon@hanyang.ac.kr
Rights & Permissions [Opens in a new window]

Abstract

n-3 and Trans fatty acids are considered to be the important modifiable factors of the metabolic syndrome. The purpose of this study was to test the hypothesis that lower Omega-3 fatty acids and/or higher trans fatty acids of erythrocytes (RBC) are associated with the risk of the metabolic syndrome. Forty-four patients with the metabolic syndrome, defined by three or more risk factors of the modified Adult Treatment Panel III criteria, and eighty-eight age- and sex-matched controls with less than three risk factors were recruited for the study. The mean age was 54·5 (sem 0·8) years and 45 % of subjects were female. Trans fatty acids of RBC were higher in patients than controls (0·82 (sem 0·04) v. 0·73 (sem 0·03) %; P = 0·043), while their Omega-3 indexes, the sum of EPA and DHA in RBC, did not significantly differ (11·78 (sem 0·04) v. 12·39 (sem 0·02) %). Multivariable-adjusted regression analysis showed positive association between trans fatty acid and risk of the metabolic syndrome (OR 7·13; 95 % CI 1·53, 33·27; P = 0·013). Fasting serum insulin (7·9 (sem 0·7) v. 4·9 (sem 0·3) μU/ml; P < 0·001) and high sensitivity C-reactive protein (18 (sem 3) v. 11 (sem 17) mg/l; P = 0·042) were also higher in patients than controls. There were significant positive relationships between trans fatty acids and waist circumference, and between trans fatty acids and BMI. The results suggested that RBC trans fatty acids might be a predictor of increased risk for the metabolic syndrome, but n-3 fatty acids were not in this population.

Type
Full Papers
Copyright
Copyright © The Authors 2008

The metabolic syndrome classically refers to a multi-component disorder that is characterized by abdominal obesity, hypertension, dyslipidaemia and impaired glucose tolerance(1). It is associated with a high risk of subsequent development of type 2 diabetes mellitus and CVD(Reference Grundy, Cleeman and Daniels2). The prevalence of the metabolic syndrome defined by the Adult Treatment Panel III criteria was 23·7 % in the Third National Examination Survey in the United States, but its prevalence was found to differ among ethnic groups(Reference Ford, Giles and Dietz3). In Korea, the prevalence of the metabolic syndrome was 29·0 % in men and 16·8 % in women aged 30–80 years when using Asian–Pacific waist criteria(Reference Oh, Hong and Sung4).

Serum fatty acid composition has been shown to predict the risk of diabetes(Reference Wang, Folsom, Zheng, Pankow and Eckfeldt5) and CVD(Reference Wang, Folsom and Eckfeldt6) and is related to components of the metabolic syndrome(Reference Tremblay, Despres and Piche7). n-3 PUFA such as EPA (20 : 5n-3) and DHA (22 : 6n-3) have beneficial effects on improving lipid profiles(Reference Mori, Burke and Puddey8, Reference Holness, Greenwood, Smith and Sugden9), reducing blood pressure(Reference Prisco, Paniccia and Bandinelli10), improving insulin resistance(Reference Mori, Burke and Puddey8, Reference Holness, Greenwood, Smith and Sugden9) and reducing markers of systemic inflammation(Reference Harris, Park and Isley11). On the other hand, intake of trans fatty acids was inversely related with HDL-cholesterol(Reference Troisi, Willett and Weiss12, Reference Mensink, Zock, Kester and Katan13) and positively related to LDL-cholesterol(Reference Troisi, Willett and Weiss12). Trans fatty acids also increased lipoprotein(a)(Reference Nestel, Noakes and Belling14), TAG(Reference Katan, Zock and Mensink15) and insulin resistance(Reference Hu, Manson and Stampfer16) and were associated with systemic inflammation and endothelial dysfunction(Reference Lopez-Garcia, Schulze and Meigs17, Reference Mozaffarian, Katan, Ascherio, Stampfer and Willett18). Thus, n-3 and trans fatty acid tissue levels may be a modifiable factor for the metabolic syndrome. The estimated dietary intake of fish is high in Korea(Reference Nogi, Yang, Li, Yamasaki, Watanabe, Hashimoto and Shiwaku19), so Korea is a particularly appropriate population to investigate the role of n-3 PUFA on the metabolic syndrome.

The purpose of the present study was to compare fatty acid composition of erythrocytes (RBC), plasma lipid profiles, high sensitivity C-reactive protein (hs-CRP), fasting glucose and insulin levels between Koreans with and without the metabolic syndrome. The Omega-3 index, a new blood test to measure EPA and DHA in RBC, as a good reflection of systemic n-3 PUFA status(Reference Harris and Von Schacky20) was also compared.

Subjects and methods

Subjects

Subjects were recruited from patients visiting for regular heath examinations at Pusan National University Hospital between August 2006 and January 2007. Cases consisted of patients diagnosed with the metabolic syndrome, defined by modified Adult Treatment Panel III criteria(1): presence of three or more of the following components: (1) a waist circumference ≥ 90 cm in men and ≥ 80 cm in women; (2) HDL-cholesterol levels < 400 mg/l in men and < 500 mg/l in women; (3) TAG level ≥ 1500 mg/l; (4) systolic blood pressure ≥ 130 mmHg or diastolic blood pressure ≥ 85mmHg or taking an anti-hypertensive medication; (5) fasting glucose levels ≥ 1100 mg/l or taking an anti-diabetic medication. We selected age- and sex-matched controls with less than three risk factors of the modified Adult Treatment Panel III criteria. The current study was approved by the Institutional Review Board of Pusan National University Hospital and informed, written consent was obtained from all subjects before participating.

Procedures

Medical history and lists of medications such as oral hypoglycaemic agents, insulin, lipid-lowering, anti-hypertensive or oestrogen agents were obtained. Weekly total fish intakes were additionally obtained from all subjects. Subjects taking a supplement containing n-3 fatty acids were excluded. Height and body weight was measured using a digital scale with the subjects wearing a light gown. BMI was calculated as weight (kg)/height (m2). Using a tape measure, waist circumference was measured up to 0·1 cm unit at the midpoint between the lower costal margin and the iliac crest by well-trained examiners. Total body fat (%) was determined using a bioelectric impedance analyser (Inbody 3·0; Biospace Co., Ltd., Seoul, Korea). Resting blood pressure was measured using an automatic sphygmomanometer (BP203RV-II; Nippon Colin, Japan) after>10 min at rest in a sitting position at 08.00 hours to 10.00 hours.

Subjects refrained from smoking or ingesting caffeine for 30 min prior to having their blood samples drawn. Fasting blood samples (>12 h) were collected from the antecubital vein to determine serum concentrations of total cholesterol, TAG, HDL-cholesterol, fasting glucose, insulin, hs-CRP, alanine aminotransferase (ALT) and alkaline phosphatase. All biochemical analyses were carried out within 2 h of blood sampling, using an autoanalyser (model 7600-110; Hitachi Corp., Tokyo, Japan) and commercially available kits. LDL-cholesterol was calculated using the Friedewald formula(Reference Friedwald, Levy and Fredrickson21). Homeostasis model assessment insulin resistance (HOMA-IR) was calculated from the fasting concentration of insulin and glucose using the following formula(Reference Matthews, Hosker and Rudenski22):

RBC were used for fatty acid analysis(Reference Harris and Von Schacky20). Boron trifluoride methanol-benzene (B1252; Sigma-Aldrich, MO, USA) was added to RBC and samples were methylated for 10 min at 100°C. Fatty acid methyl esters were analysed by GC (Shimadzu 2010AF; Shimadzu Scientific Instrument, Japan) with a 100 mm SP2560 capillary column (Supelco; Bellefonte, PA, USA). Standard (GLC-727; Nu-Check Prep, Elysian, MN, USA) was used for identifying fatty acids and correcting inter-assay variation. In the standard, 18 : 1t peak was the mixture of 18 : 1n-12t, C18 : 1n-9t and 18 : 1n-7t, while 18 : 2n-6t peak contained 18 : 2n-6tt. The Omega-3 index was calculated as the sum of EPA and DHA in RBC. The control sample composed of pooled RBC and CV was 6·2 %.

Statistical analysis

All data were expressed as mean with their standard errors of the mean. Subjects with and without the metabolic syndrome were compared using the independent t test, and correlation between variables was tested by partial correlation analysis after adjusting age and sex. OR were computed for specific fatty acids of interest using multivariable logistic regression analysis after adjusting for age, sex, height, weight, blood pressure, aspirate aminotransferase, ALT, hs-CRP, glucose, insulin, TAG, total cholesterol, HDL-cholesterol, LDL-cholesterol and waist circumference. Fatty acid values were categorized into quartiles based on the control data only and then second and third quartiles were combined. Statistical analysis was performed using SPSS 12.0 (SPSS Inc., Chicago, IL, USA). A P value of < 0·05 was considered statistically significant.

Results

General characteristics of subjects

The characteristics of subjects are shown in Table 1. Weight, BMI and waist circumference were significantly (P < 0·001) higher in the patients with the metabolic syndrome than those without it. Waist circumference (95·5 %) was the most common determinant risk factor in cases, and there were 63·6 % of cases with three risk factors and 34·1 % and 2·3 % of cases with four and five risk factors, respectively. On the other hand, 52·4 %, 23·8 %, 23·8 % of controls had one, none, two risk factor(s), respectively.

Table 1 General characteristics of subjects

(Mean values with their standard errors)

Mean values were significantly different: *P < 0·001 (independent t test).

For details of subjects and procedures, see Subjects and methods.

Metabolic parameters and fish intake

Diastolic and systolic blood pressure, ALT, hs-CRP, fasting blood glucose, serum insulin, HOMA-IR and TAG were significantly (P < 0·05) higher in the patients with the metabolic syndrome than those without it (Table 2). On the other hand, HDL-cholesterol was significantly (P < 0·001) lower in the patients than in controls. There was no significant difference in the weekly fish consumption between the patients and the control subjects (2·80 servings/week v. 3·11 servings/week). However, subjects with higher fish consumption had a greater Omega-3 index (Fig. 1).

Table 2 Metabolic parameters of subjects

(Mean values with their standard errors)

AST, aspirate aminotransferase; ALT, alanine aminotransferase; hs-CRP, high sensitivity C-reactive protein; HOMA-IR, homeostasis model assessment of insulin resistance, calculated from (fasting insulin (μU/ml) ×  fasting glucose (mg/dl))/405.

Mean values were significantly different: *P < 0·05; **P < 0·001 (independent t test).

For details of subjects and procedures, see Subjects and methods.

Fig. 1 Quartile of weekly fish intake and Omega-3 index (thirty-three in each). a,b Mean values with different letters were significantly different: P < 0·05 (ANOVA with post-hoc by Tukey's test).

Erythrocyte fatty acid composition

Fatty acid composition of RBC is presented in Table 3. Trans fatty acids of RBC were significantly (P = 0·043) higher in patients than controls, while the Omega-3 index did not differ between groups. Total PUFA was significantly lower, but 14 : 0, 16 : 1n-t, 18 : 1n-9c, 18 : 2n-6t, 18 : 3n-3 and MUFA were significantly (P < 0·05) higher in the patients with than those without the metabolic syndrome. However, multivariable-adjusted regression analysis showed that only total trans fatty acids and 18 : 2n-6tt were positively (P < 0·05) associated with risk of the metabolic syndrome after adjusting for age, sex, height, weight, blood pressure, aspirate aminotransferase, ALT, hs-CRP, glucose, insulin, TAG, total cholesterol, HDL-cholesterol, LDL-cholesterol and waist circumference (Table 4). Subjects in the highest quartile of total trans fatty acids and 18 : 2n-6tt had seven and fourteen times higher risk of the metabolic syndrome, even after adjusting for all confounding variables. Total trans fatty acids (P = 0·01), 16 : 1n-7t (P = 0·045) and 18 : 2n-6tt (P = 0·007), 14 : 0 (SFA; P < 0·001) and MUFA were positively (P = 0·014) related with waist circumference (Table 5). BMI was positively associated with 14 : 0 (P < 0·001) and MUFA (P = 0·031), but negatively associated with PUFA (P = 0·023) and n-6 PUFA (P = 0·006). TAG levels were positively related with 14 : 0 (P < 0·001), 18 : 1n-9c (P < 0·001), 16 : 1 n-7t (P = 0·009) and MUFA (P < 0·001). C-reactive protein was positively related with SFA (P = 0·023), but negatively with PUFA (P = 0·004) and n-6 PUFA (P = 0·036). In addition, 14 : 0 was positively associated with glucose (P = 0·009), insulin (P < 0·001) and HOMA-IR (P < 0·001).

Table 3 Fatty acid composition of erythrocytes in subjects

(Mean values with their standard errors of the mean)

Omega-3 index, DHA+EPA.

Mean values were significantly different: *P < 0·05; **P < 0·001 (independent t test).

For details of subjects and procedures, see Subjects and methods.

Table 4 OR and 95 % CI associated with fatty acid composition and the risk of the metabolic syndrome by multivariable regression analysis*

RBC, erythrocytes.

* For details of subjects and procedures, see Subjects and methods.

Second quartile+third quartile.

OR was adjusted for age, sex, height, weight, blood pressure, aspirate aminotransferase, alanine aminotransferase, high sensitivity C-reactive protein, glucose, insulin, TAG, total cholesterol, HDL-cholesterol, LDL-cholesterol and waist circumference.

Table 5 Correlation between fatty acid composition and metabolic parameters by partial correlation analysis

hs-CRP, high sensitivity C-reactive protein; HOMA-IR, homeostasis model assessment of insulin resistance, calculated from (fasting insulin (μU/ml) × fasting glucose (mg/dl))/405.

All values were significantly different: *P < 0·05; **P < 0·001 (partial correlation coefficient adjusted by age and sex).

For details of subjects and procedures, see Subjects and methods.

Discussion

In the present study, we observed that RBC trans fatty acids were higher in patients with than without the metabolic syndrome and associated with risk of the metabolic syndrome after adjusting for age, sex, height, weight, blood pressure, aspirate aminotransferase, ALT, hs-CRP, glucose, insulin, TAG, total cholesterol, HDL-cholesterol, LDL-cholesterol and waist circumference. However, the Omega-3 index might not be associated with the metabolic syndrome in this population. Total MUFA, PUFA, trans fatty acid, 14 : 0, 16 : 1n-7t, 18 : 1n-9c, 18 : 2n-6tt and 18 : 3n-3 differed between patients and controls, but after adjusting for all metabolic parameters only trans fatty acids and 18 : 2n-6tt were significantly different. Correlation analysis showed that RBC fatty acids were significantly related with mostly TAG, waist circumference and BMI, which might be the major factors accounted for the OR analysis.

Trans fatty acids are positively related with lipoprotein(a)(Reference Nestel, Noakes and Belling14), systemic inflammation, endothelial dysfunction and plasma TAG levels(Reference Katan, Zock and Mensink15) and strongly associated with CVD(Reference Mozaffarian, Katan, Ascherio, Stampfer and Willett18, Reference Sun, Ma, Campos and Hankinson23). Thus, it is possible that trans fatty acids play a role in the development of the metabolic syndrome and type 2 diabetes mellitus(Reference Lopez-Garcia, Schulze and Meigs17, Reference Mozaffarian, Katan, Ascherio, Stampfer and Willett18). In a large prospective study of women, intake of trans fatty acids was positively associated with type 2 diabetes(Reference Salmeron, Hu and Manson24). Sun et al. (Reference Sun, Ma, Campos and Hankinson23) reported that the risk for CHD among subjects in the highest quartile of erythrocyte trans fatty acid content was three times higher than that of subjects in the lowest quartile. Troisi et al. (Reference Troisi, Willett and Weiss12) reported that intake of trans fatty acids was positively related to LDL-cholesterol and inversely related to HDL-cholesterol. Meta-analysis of Mensink et al. (Reference Mensink, Zock, Kester and Katan13) showed that trans fatty acids raised the serum total cholesterol:HDL ratio. Koh-Banerjee et al. (Reference Koh-Banerijee, Chu, Spiegelman, Rosner, Colditz, Willett and Rim25) reported a positive association between intake of trans fatty acids and abdominal adiposity in the prospective cohort. Kavanagh et al. (Reference Kavanagh, Jones, Sawyer, Kelley, Carr, Wagner and Rudel26) also showed that trans fatty acids were an independent factor for abdominal fat deposition and impaired insulin sensitivity, both of which are linked to the metabolic syndrome.

Recently, the Korean Food and Drug Administration reported that the average intake of trans fat was estimated as 0·7 % total energy or 1·54 g trans fat per d, which was lower than the WHO recommendation of less than 1 % total energy(Reference Hunter27). The average trans fatty acid of the current subjects was 0·73 % in RBC, which was also lower than those of the USA (2·0 %) and Denmark (1·2 %)(Reference Hunter27, Reference Dyerberg, Eskesen and Andersen28). Although RBC trans fatty acids were relatively low in all subjects, they were different between patients and controls, possibly suggesting the association between trans fatty acid and the metabolic syndrome.

Interestingly, we found higher 18 : 2n-6tt and lower 18 : 1t in RBC of subjects as compared with those of Westerners. The main contributors for trans 18 : 2n-6tt are vegetable oils (maize oil, soyabean oil, sesame oil), mayonnaise and canned tuna, while dairy products such as cheese, milk, ice cream, sour cream and butter contain 18 : 1t(Reference Karabulut29, Reference Baylin, Siles, Donovan-Palmer, Fernandez and Campos30). It is known that consumption of dairy products is relatively low among Koreans. Thus, this discrepancy can be explained by the dietary pattern between Koreans and Westerners.

Studies have suggested that the genetic regulatory effects of PUFA may protect against the adverse signs of the metabolic syndrome by mediating insulin and carbohydrate control of lipogenic and glycolytic genes, inhibiting fat storage and promoting fat oxidation(Reference Clarke31, Reference Clarke32). Tai et al. (Reference Tai, Corella and Demissie33) found significant gene–nutrient interactions between the PPAR-α gene-leucine to valine (PPARα-L162V) polymorphism and PUFA intake on plasma TAG and apo C-III concentrations in a Framingham Heart Study. In addition, the fatty acid composition in patients with insulin resistance and the metabolic syndrome is typically characterized by high levels of SFA and low levels of PUFA(Reference Warensjö, Sundström, Lind and Vessby34). The present study did not find a difference in PUFA between patients and controls, but PUFA was negatively correlated with hs-CRP and BMI.

n-3 PUFA have beneficial effects in reducing plasma TAG(Reference Mori, Burke and Puddey8), blood pressure(Reference Troisi, Willett and Weiss12) and markers of systemic inflammation such as hs-CRP(Reference Mensink, Zock, Kester and Katan13) and also in improving the lipoprotein profile by decreasing the fraction of atherogenic small dense LDL-cholesterol and improving insulin resistance(Reference Mori, Burke and Puddey8, Reference Holness, Greenwood, Smith and Sugden9). However, studies showed that EPA and DHA were not significantly different in patients with the metabolic syndrome(Reference Warensjö, Sundström, Lind and Vessby34, Reference Klein-Platat, Drai, Oujaa, Schlienger and Simon35). We also found no significant association between fish consumption and the metabolic syndrome, and between the Omega-3 index and the metabolic syndrome. In the present study, average fish consumption was three servings per week and was greater than that of US residents, who consumed less than one serving/week(Reference Sands, Reid, Windsor and Harris36, Reference Mozaffarian, Bryson and Lemaitre37). Although the Omega-3 index was not significantly (11·8 (sem 2·5) % v. 12·4 (sem 1·9) %, P = 0·123) different between patients with and without the metabolic syndrome, it was higher than in US residents and Europeans (4 %). The current subjects consumed more than the American Heart Association recommendation of fish(Reference Kris-Etherton, Harris and Appel38) and had a higher Omega-3 index than the recommended value of 8–10 % to prevent CHD(Reference Harris and Von Schacky20). This may be explained by the fact that Pusan is a major port for the Korean fish market; thus, most people may have higher fish consumption than the general population. The average Omega-3 index was 4 % in the USA(Reference Albert, Campos and Stampfer39) and Europe(40); thus, Korea is a particularly appropriate population to investigate the role of n-3 PUFA.

In conclusion, this study showed that RBC trans fatty acid content was higher in patients with the metabolic syndrome compared with controls and was associated with risk of the metabolic syndrome after adjusting for age, sex and metabolic parameters. Although causal relationships cannot be ascertained in such a case–control study, these findings have suggested that trans fatty acids might contribute to the metabolic syndrome phenotype. Even though there was no relationship with the Omega-3 index, further studies in populations with lower fish intake regarding the relationship between fish intake and the metabolic syndrome should be undertaken.

Acknowledgements

This work was supported by the Korea Science and Engineering Foundation (KOSEF) grant founded by the Korean government (MOST) (R01-2007-000-10 613-0).

References

1 National Cholesterol Education Program (2001) Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 295, 24862497.Google Scholar
2 Grundy, SM, Cleeman, JL, Daniels, SR, et al. (2005) Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112, 27352752.CrossRefGoogle ScholarPubMed
3 Ford, ES, Giles, WS & Dietz, WH (2002) Prevalence of the metabolic syndromes among US adults: findings from the Third National Health and Nutrition Examination Survey. JAMA 287, 356359.CrossRefGoogle ScholarPubMed
4 Oh, JY, Hong, YS & Sung, YA (2004) Prevalence and factor analysis of metabolic syndromes in urban Korean population. Diabetes Care 27, 20272032.CrossRefGoogle ScholarPubMed
5 Wang, L, Folsom, AR, Zheng, ZJ, Pankow, JS & Eckfeldt, JH (2003) Plasma fatty acid composition and incidence of diabetes in middle-aged adults: the Atherosclerosis Risk in Communities (ARIC) Study. Am J Clin Nutr 78, 9198.CrossRefGoogle ScholarPubMed
6 Wang, L, Folsom, AR & Eckfeldt, JH (2003) Plasma fatty acid composition and incidence of coronary heart disease in middle-aged adults: the Atherosclerosis Risk in Communities (ARIC) Study. Nutr Metab Cardiovasc Dis 13, 256266.CrossRefGoogle ScholarPubMed
7 Tremblay, AJ, Despres, JP, Piche, ME, et al. (2004) Associations between the fatty acid content of triglyceride, visceral adipose tissue accumulation, and components of the insulin resistance syndrome. Metabolism 53, 310317.CrossRefGoogle ScholarPubMed
8 Mori, TA, Burke, V, Puddey, IB, et al. (2000) Purified eicosapentaenoic and docosahexaenoic acids have differential effects on serum lipids and lipoproteins, LDL particle size, glucose, and insulin in mildly hyperlipidemic men. Am J Clin Nutr 71, 10851094.CrossRefGoogle ScholarPubMed
9 Holness, MJ, Greenwood, G, Smith, N & Sugden, M (2003) Diabetogenic impact of long chain omega-3 acids on pancreatic beta-cell function and the regulation of endogenous glucose production. Endocrinology 144, 39583968.CrossRefGoogle ScholarPubMed
10 Prisco, D, Paniccia, R, Bandinelli, B, et al. (1998) Effect of medium-term supplementation with a moderate dose of n-3 polyunsaturated fatty acids on blood pressure in mild hypertensive patients. Thromb Res 91, 103112.CrossRefGoogle ScholarPubMed
11 Harris, WS, Park, YS & Isley, WL (2003) Cardiovascular disease and long-chain omega-3 fatty acids. Curr Opin Lipidol 14, 914.CrossRefGoogle ScholarPubMed
12 Troisi, R, Willett, WC & Weiss, ST (1992) Trans-fatty acid intake in relation to serum lipid concentrations in adult men. Am J Clin Nutr 56, 10191024.CrossRefGoogle ScholarPubMed
13 Mensink, RP, Zock, PL, Kester, AD & Katan, MB (2003) Effects of dietary fatty acids and carbohydrates on the ratio of serum total to HDL cholesterol and on serum lipids and apolipoproteins: a meta-analysis of 60 controlled trials. Am J Clin Nutr 77, 11461155.CrossRefGoogle ScholarPubMed
14 Nestel, P, Noakes, M, Belling, B, et al. (1992) Plasma lipoprotein lipid and Lp[a] changes with substitution of elaidic acid for oleic acid in the diet. J Lipid Res 33, 10291036.CrossRefGoogle ScholarPubMed
15 Katan, MB, Zock, PL & Mensink, RP (1995) Trans fatty acids and their effects on lipoproteins in humans. Annu Rev Nutr 15, 473493.CrossRefGoogle ScholarPubMed
16 Hu, FB, Manson, JE, Stampfer, MJ, et al. (2001) Diet, lifestyle, and the risk of type 2 diabetes mellitus in women. N Engl J Med 345, 790797.CrossRefGoogle ScholarPubMed
17 Lopez-Garcia, E, Schulze, MB, Meigs, JB, et al. (2005) Consumption of trans fatty acids is related to plasma biomarkers of inflammation and endothelial dysfunction. J Nutr 135, 562566.CrossRefGoogle Scholar
18 Mozaffarian, D, Katan, MB, Ascherio, A, Stampfer, MJ & Willett, WC (2006) Trans fatty acids and cardiovascular disease. N Engl J Med 354, 16011613.CrossRefGoogle ScholarPubMed
19 Nogi, A, Yang, J, Li, L, Yamasaki, M, Watanabe, M, Hashimoto, M & Shiwaku, K (2007) Plasma n-3 polyunsaturated fatty acid and cardiovascular disease risk factors in Japanese, Korean and Mongolian workers. J Occup Health 49, 205216.CrossRefGoogle ScholarPubMed
20 Harris, WS & Von Schacky, C (2004) The omega-3 index: a new risk factor for death from coronary heart disease? Prev Med 39, 212220.CrossRefGoogle ScholarPubMed
21 Friedwald, WT, Levy, RI & Fredrickson, DS (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18, 499502.CrossRefGoogle Scholar
22 Matthews, DR, Hosker, JP, Rudenski, AS, et al. (2003) Impact of glucose intolerance and insulin resistance on cardiac structure and function: sex-related differences in the Framingham Heart Study. Circulation 107, 448454.Google Scholar
23 Sun, Q, Ma, J, Campos, H, Hankinson, SE, et al. (2007) A prospective study of trans fatty acids in erythrocytes and risk of coronary heart disease. Circulation 115, 18581865.CrossRefGoogle ScholarPubMed
24 Salmeron, J, Hu, FB, Manson, JE, et al. (2001) Dietary fat intake and risk of type 2 diabetes in women. Am J Clin Nutr 73, 10191022.CrossRefGoogle ScholarPubMed
25 Koh-Banerijee, P, Chu, N, Spiegelman, D, Rosner, B, Colditz, G, Willett, W & Rim, E (2003) Prospective study of the association of changes in dietary intake, physical activity, alcohol consumption, and smoking with 9-y gain in waist circumference among 16587 US men. Am J Clin Nutr 78, 719727.CrossRefGoogle Scholar
26 Kavanagh, K, Jones, KL, Sawyer, J, Kelley, K, Carr, JJ, Wagner, JD & Rudel, LL (2007) Trans fat diet induces abdominal obesity and changes in insulin sensitivity in monkeys. Obesity 15, 16751684.CrossRefGoogle ScholarPubMed
27 Hunter, JE (2006) Dietary trans fatty acids: review of recent human studies and food industry response. Lipids 41, 967992.CrossRefGoogle Scholar
28 Dyerberg, J, Eskesen, DC, Andersen, PW, et al. (2004) Effects of trans- and n-3 unsaturated fatty acids on cardiovascular risk markers in healthy males. An 8 weeks dietary intervention study. Eur J Clin Nutr 58, 10621070.CrossRefGoogle ScholarPubMed
29 Karabulut, I (2007) Fatty acid composition of frequently consumed foods in Turkey with special emphasis on trans fatty acids. Int J Food Sci Nutr 1, 110.Google Scholar
30 Baylin, A, Siles, X, Donovan-Palmer, A, Fernandez, X & Campos, H (2007) Fatty acid composition of Costa Rican foods including trans fatty acid content. J Food Comp Analysis 20, 182192.CrossRefGoogle Scholar
31 Clarke, SD (2000) Polyunsaturated fatty acid regulation of gene transcription: a mechanism to improve energy balance and insulin resistance. Br J Nutr 8, S59S66.CrossRefGoogle Scholar
32 Clarke, SD (2001) Polyunsaturated fatty acid regulation of gene transcription a molecular mechanism to improve the metabolic syndrome. J Nutr 131, 11291132.CrossRefGoogle ScholarPubMed
33 Tai, ES, Corella, D, Demissie, S, et al. (2005) Polyunsaturated fatty acids interact with the PPARA-L162V polymorphism to affect plasma triglyceride and apolipoprotein C-III concentrations in the Framingham Heart Study. J Nutr 135, 397403.CrossRefGoogle ScholarPubMed
34 Warensjö, E, Sundström, J, Lind, L & Vessby, B (2006) Factor analysis of fatty acids in serum lipids as a measure of dietary fat quality in relation to the metabolic syndrome in men. Am J Clin Nutr 84, 442448.CrossRefGoogle Scholar
35 Klein-Platat, C, Drai, J, Oujaa, M, Schlienger, JL & Simon, C (2005) Plasma fatty acid composition is associated with the metabolic syndrome and low-grade inflammation in overweight adolescents. Am J Clin Nutr 82, 11781184.CrossRefGoogle ScholarPubMed
36 Sands, SA, Reid, KJ, Windsor, SL & Harris, WS (2005) The impact of age, body mass index, and fish intake on the EPA and DHA content of human erythrocytes. Lipids 40, 343347.CrossRefGoogle ScholarPubMed
37 Mozaffarian, D, Bryson, CL, Lemaitre, RN, et al. (2005) Fish intake and risk of incident heart failure. J Am Coll Cardiol 45, 20152021.CrossRefGoogle ScholarPubMed
38 Kris-Etherton, PM, Harris, WS, Appel, LJ & American Heart Association Nutrition Committee (2002) Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation 106, 27472757.CrossRefGoogle ScholarPubMed
39 Albert, CM, Campos, H, Stampfer, MJ, et al. (2002) Blood levels of long-chain n-3 fatty acids and the risk of sudden death. N Engl J Med 346, 11131118.CrossRefGoogle ScholarPubMed
40 GISSI-Prevenzione Investigators (1999) Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E in 11,324 patients with myocardial infarction: results of the GISSI-Prevenzione trial. Lancet 354, 447455.CrossRefGoogle Scholar
Figure 0

Table 1 General characteristics of subjects†(Mean values with their standard errors)

Figure 1

Table 2 Metabolic parameters of subjects†(Mean values with their standard errors)

Figure 2

Fig. 1 Quartile of weekly fish intake and Omega-3 index (thirty-three in each). a,b Mean values with different letters were significantly different: P < 0·05 (ANOVA with post-hoc by Tukey's test).

Figure 3

Table 3 Fatty acid composition of erythrocytes in subjects†(Mean values with their standard errors of the mean)

Figure 4

Table 4 OR and 95 % CI associated with fatty acid composition and the risk of the metabolic syndrome by multivariable regression analysis*

Figure 5

Table 5 Correlation between fatty acid composition and metabolic parameters by partial correlation analysis†